Dacarbazine

DEA Class; Rx

Common Brand Names; DTIC Dome

  • Antineoplastics, Alkylating

Alkylating antineoplastic agent; used in the treatment of melanoma, sarcoma, and Hodgkin’s disease.

Indicated for the treatment of metastatic malignant melanoma.

For the treatment of Hodgkin lymphoma.
For the treatment of unresectable or metastatic osteogenic sarcoma, in combination with mesna, ifosfamide, and doxorubicin.
For the treatment of of unresectable or metastatic Ewing’s sarcoma, in combination with mesna, ifosfamide, and doxorubicin.

Hypersensitivity

Breastfeeding

Severe anemia, severe thrombocytopenia

  • Nausea (>90%)
  • Vomiting(>90%)
  • Injection site pain
  • Leukopenia
  • Thrombocytopenia
  • Alopecia
  • Rash
  • Photosensitivity
  • Anorexia
  • Metallic taste
  • Flu-like syndrome

Caution in hepatic/renal impairment; monitor for toxicity

May cause severe pain & burning at injection site & along vein; to alleviate, may increase diluent, reduce infusion rate & apply cold compresses

Risk of potentially fatal hepatocellular necrosis

Avoid pregnancy

Pregnancy Category: C

Lactation: not known if excreted in breast milk, do not nurse

Adults

1000 mg/m2 IV as a single dose.

Elderly

1000 mg/m2 IV as a single dose.

Adolescents

375 mg/m2 IV as a single dose; single doses of 900 mg/m2 IV have been given off-label for neuroblastoma.

Children

375 mg/m2 IV as a single dose; single doses of 900 mg/m2 IV have been given off-label for neuroblastoma.

Dacarbazine

powder for injection

  • 100mg
  • 200mg

About the Author

You may also like these

0